Literature DB >> 26726941

Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.

S Hong1, J Valent2, L Rybicki3, D Abounader4, B Bolwell2,4, R Dean2,4, A T Gerds2,4, D Jagadeesh2,4, B K Hamilton2,4, B Hill2,4, M E Kalaycio2,4, B Pohlman2,4, F Reu2,4, C Samaras2,4, R Sobecks2,4, N S Majhail2,4, H D Liu2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26726941     DOI： 10.1038/bmt.2015.326

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Authors:  Vaishali Sanchorawala; Fangui Sun; Karen Quillen; J Mark Sloan; John L Berk; David C Seldin
Journal:  Blood       Date:  2015-10-06       Impact factor: 22.113

2.  Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; Dennis A Gastineau
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

3.  Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

Authors:  Emma C Scott; Stephen B Heitner; William Dibb; Gabrielle Meyers; Stephen D Smith; Farnoush Abar; Tibor Kovacsovics; Galit Perez-Avraham; Alex Stentz; Rachel Frires; James Dibb; Richard T Maziarz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-16

4.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 5.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Authors:  R L Comenzo; D Reece; G Palladini; D Seldin; V Sanchorawala; H Landau; R Falk; K Wells; A Solomon; A Wechalekar; J Zonder; A Dispenzieri; M Gertz; H Streicher; M Skinner; R A Kyle; G Merlini
Journal:  Leukemia       Date:  2012-04-05       Impact factor: 11.528

6.  Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.

Authors:  Vaishali Sanchorawala; Dina Brauneis; Anthony C Shelton; Stephen Lo; Fangui Sun; J Mark Sloan; Karen Quillen; David C Seldin
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-06       Impact factor: 5.742

7.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

Review 8.  Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.

Authors:  S O Schönland; P Dreger; T de Witte; U Hegenbart
Journal:  Bone Marrow Transplant       Date:  2011-07-25       Impact factor: 5.483

9.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

10.  Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.

Authors:  Xianghua Huang; Qingwen Wang; Wencui Chen; Caihong Zeng; Zhaohong Chen; Dehua Gong; Haitao Zhang; Zhihong Liu
Journal:  BMC Med       Date:  2014-01-06       Impact factor: 8.775
View more
  3 in total

1.  Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population.

Authors:  Rajshekhar Chakraborty; Lisa Rybicki; Jacqulyn Tomer; Christy J Samaras; Beth M Faiman; Jason Valent; Navneet S Majhail
Journal:  Leuk Lymphoma       Date:  2019-07-05

2.  Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.

Authors:  Robert F Cornell; Raphael Fraser; Luciano Costa; Stacey Goodman; Noel Estrada-Merly; Cindy Lee; Gerhard Hildebrandt; Usama Gergis; Nosha Farhadfar; César O Freytes; Rammurti T Kamble; Maxwell Krem; Robert A Kyle; Hillard M Lazarus; David I Marks; Kenneth Meehan; Sagar S Patel; Muthalagu Ramanathan; Richard F Olsson; John L Wagner; Shaji Kumar; Muzaffar H Qazilbash; Ninah Shah; Parameswaran Hari; Anita D'Souza
Journal:  Transplant Cell Ther       Date:  2020-12-16

3.  Deferred autologous stem cell transplantation in systemic AL amyloidosis.

Authors:  Richa Manwani; Ute Hegenbart; Shameem Mahmood; Sajitha Sachchithanantham; Charalampia Kyriakou; Kwee Yong; Rakesh Popat; Neil Rabin; Carol Whelan; Tobias Dittrich; Christoph Kimmich; Philip Hawkins; Stefan Schönland; Ashutosh Wechalekar
Journal:  Blood Cancer J       Date:  2018-11-05       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.